TD Asset Management Inc Sells 21,228 Shares of Scholar Rock Holding Corporation $SRRK

TD Asset Management Inc lessened its stake in shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) by 6.4% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 312,398 shares of the company’s stock after selling 21,228 shares during the period. TD Asset Management Inc’s holdings in Scholar Rock were worth $11,634,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in SRRK. Moody Aldrich Partners LLC grew its stake in shares of Scholar Rock by 53.5% in the third quarter. Moody Aldrich Partners LLC now owns 101,742 shares of the company’s stock valued at $3,789,000 after buying an additional 35,481 shares in the last quarter. Norges Bank acquired a new stake in Scholar Rock in the second quarter valued at $41,628,000. Voya Investment Management LLC grew its position in shares of Scholar Rock by 18.1% in the 3rd quarter. Voya Investment Management LLC now owns 443,155 shares of the company’s stock valued at $16,503,000 after acquiring an additional 67,839 shares during the period. Nan Fung Trinity HK Ltd. acquired a new position in shares of Scholar Rock during the 3rd quarter worth about $1,402,000. Finally, Ensign Peak Advisors Inc increased its stake in shares of Scholar Rock by 78.8% during the 2nd quarter. Ensign Peak Advisors Inc now owns 600,639 shares of the company’s stock worth $21,275,000 after purchasing an additional 264,693 shares during the last quarter. Institutional investors and hedge funds own 91.08% of the company’s stock.

Scholar Rock Trading Down 1.3%

Shares of Scholar Rock stock opened at $44.27 on Monday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.30 and a current ratio of 6.30. The firm has a 50-day moving average of $45.36 and a 200-day moving average of $38.91. Scholar Rock Holding Corporation has a 52-week low of $22.71 and a 52-week high of $49.82. The stock has a market cap of $4.52 billion, a PE ratio of -14.05 and a beta of 0.70.

Insider Buying and Selling at Scholar Rock

In other Scholar Rock news, insider Jing L. Marantz sold 4,157 shares of the stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $46.53, for a total transaction of $193,425.21. Following the transaction, the insider owned 126,012 shares in the company, valued at $5,863,338.36. This represents a 3.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Caryn Parlavecchio sold 9,035 shares of Scholar Rock stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $46.53, for a total transaction of $420,398.55. Following the completion of the sale, the insider owned 169,087 shares of the company’s stock, valued at approximately $7,867,618.11. The trade was a 5.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 344,932 shares of company stock worth $15,371,225. 13.30% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts have weighed in on SRRK shares. Wolfe Research started coverage on Scholar Rock in a research report on Tuesday, November 18th. They set an “outperform” rating and a $42.00 price target on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Scholar Rock in a report on Thursday, December 11th. HC Wainwright raised their price target on Scholar Rock from $44.00 to $58.00 and gave the company a “buy” rating in a report on Monday, January 26th. BMO Capital Markets reaffirmed an “outperform” rating and set a $50.00 price objective on shares of Scholar Rock in a research report on Friday, November 14th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Scholar Rock in a research note on Thursday, January 22nd. Four investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $51.14.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).